Nasdaq panel approves Dare Bioscience's compliance plan; deadline Aug 12, 2025

Dare Bioscience, Inc.

Panel approved modified plan to regain compliance with Nasdaq Listing Rules 5550(b)(1) (≥$2.5M equity) or 5550(b)(2) (≥$35M MVLS).
Must demonstrate compliance by July 31, 2025; conditional listing ends August 12, 2025.
If plan fails, Nasdaq may delist common stock before August 12, 2025.
Company has been non-compliant with Rule 5550(b) since August 2024.
No assurances given that compliance will be achieved by the deadlines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.